Prescribing Information
touchSYMPOSIUM HIGHLIGHTS Treatment decisions in high-risk* acute myeloid leukaemia: what is the ultimate goal?
Watch leading experts present and discuss the latest developments in the assessment and treatment of high-risk* acute myeloid leukaemia.
*High risk AML is defined as newly diagnosed, therapy related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC).
Is treatment with curative intent the ultimate goal?
Is intensive chemotherapy the antileukaemic standard of care?
How should MRD assessment inform treatment decisions?
Pursuing long-term survival in the real world
Overview
High-risk* acute myeloid leukaemia (AML) has a poor prognosis and remains a therapeutic challenge.1 In this sponsored Symposium, leading experts present and discuss the latest developments in the assessment and treatment of high-risk AML, including the importance of measurable residual disease and the use of Vyxeos Liposomal (CTX-351).2–4
*High risk AML is defined as newly diagnosed, therapy related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC).
Prof. Mohamad Mohty
Professor and Head of the Hematology and Cellular Therapy Department at the Saint-Antoine Hospital, University Pierre & Marie Curie, Paris, France read more
Prof. Thomas Cluzeau
Professor and Head of the Department of Haematology at CHU of Nice, Côte d’Azur University, Nice, France
Prof. Martin BornhÓ“user
Professor of Haematology at the University Hospital Carl Gustav Carus, Dresden, Germany
Prof. Gert Ossenkoppele
Professor of Hematology at the VU University Medical Center, Amsterdam, The Netherlands
Prof. Adriano Venditti
Professor of Haematology at the University of Rome Tor Vergata, Rome, Italy
Prof. Thomas Schroeder
Head of Stem Cell Transplantation, University Hospital Essen, Essen, Germany
Disclosures
Prof. Mohamad Mohty
Honoraria: Adaptive Biotechnologies, Amgen, Astellas, Celgene-BMS, GSK, Gilead, Janssen, Jazz Pharmaceuticals, Novartis, Oncopeptides, Pfizer, Sanofi & Takeda. Research/project funding: Janssen & Sanofi.
Prof. Thomas Cluzeau
Advisory board: AbbVie, Agios, BMS-Celgene, Jazz Pharmaceuticals, Novartis & Servier. Invited speaker/education: Amgen, Astellas, BMS-Celgene, Jazz Pharmaceuticals, Novartis, Pfizer & Sanofi. Research/project funding: Alexion, Amgen, Aprea, Arog, BMS-Celgene, Jazz Pharmaceuticals, Kartos, Novartis & Syros.
Prof. Martin BornhÓ“user
Advisory board: Alexion, Jazz Pharmaceuticals, Merck Sharp & Dohme. Honoraria: BMS-Celgene, Jazz Pharmaceuticals, Merck Sharp & Dohme. Novartis. Research/project funding: Miltenyi Biotec.
Prof. Gert Ossenkoppele
Advisory board: Agios Pharmaceuticals, Amgen, Astellas, Bristol Myers Squibb, Celgene, Gilead, Jazz Pharmaceuticals, Johnson & Johnson, MERUS, Novartis, Pfizer & Roche. Consultancy: Celgene, Johnson & Johnson, Roche. Research/project funding: Celgene, Johnson & Johnson, Novartis.
Prof. Adriano Venditti
Consultancy: AbbVie, Amgen, Astellas, AstraZeneca, Janssen, Jazz Pharmaceuticals, Medac, Novartis & Pfizer. Invited speaker/education: AbbVie, AstraZeneca, BMS-Celgene, Janssen & Jazz Pharmaceuticals. Project/research funding: Sandoz.
Prof. Thomas Schroeder
Consultancy: AbbVie, Bristol Myers Squibb, Celgene, Jazz Pharmaceuticals, Pfizer & Takeda. Invited speaker/education: AbbVie; Bristol Myers Squibb, Celgene, Jazz Pharmaceuticals, Pfizer & Takeda. Honoraria: AbbVie, Bristol Myers Squibb, Celgene & Jazz Pharmaceuticals. Project/research: Celgene-BMS & Jazz Pharmaceuticals.
Learning Objectives & Overview
Overview
High-risk* acute myeloid leukaemia (AML) has a poor prognosis and remains a therapeutic challenge.1 In this sponsored Symposium, recorded at the 5th Annual Meeting of the International Academy for Clinical Haematology, six leading experts present and discuss key aspects of high-risk AML treatment, including the importance of measurable residual disease, and clinical/real-world evidence for the use of Vyxeos Liposomal (Daunorubicin 44 mg / Cytarabine 100 mg)2–4
*High risk AML is defined as newly diagnosed, therapy related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC).
Learning Objectives
After watching this activity, participants should be better able to:
- Describe the key treatment goals and factors influencing treatment decisions in high-risk* AML
- Discuss the role of measurable residual disease in the management of high-risk* AML
- Review the clinical and real-world evidence on the use of Vyxeos Liposomal (CTX-351) for the treatment of high-risk* AML
Adverse Events
Adverse Events
Adverse events should be reported. Healthcare professionals are asked to report any suspected adverse events via their national reporting system. Adverse events should also be reported to Jazz Pharmaceuticals by email to aereporting@jazzpharma.com
References
References
- Granfeldt Østgård LS, et al. Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort study. J Clin Oncol. 2015;33:3641–9.
- Lancet JE, et al. CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol. 2021;8:e481–e491.
- Chiche E, et al. Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort. Blood Adv. 2021;5:176–184.
- Guolo F, et al. CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program. Blood Cancer J. 2020;10:96.